Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance

Blood Cancer Journal

Volumn 3, Issue 9, 2013, Pages

  Bryant, C ^a,b,c   Suen, H ^a,d   Brown, R ^a   Yang, S ^a   Favaloro, J ^a   Aklilu, E ^a   Gibson, J ^a   Ho, P J ^a   Iland, H ^a   Fromm, P ^b,c   Woodland, N ^d   Nassif, N ^d   Hart, D ^b,c   Joshua, D E ^a,c  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b Department of Microbiology and Infectious Diseases   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CANCER SURVIVOR; CELL EXPANSION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DONOR; FEMALE; FOLLOW UP; HUMAN; IN VITRO STUDY; LONG TERM SURVIVAL; LYMPHOCYTE CLONE; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; REGULATORY T LYMPHOCYTE; TH17 CELL;

EID: 84885350915     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2013.34     Document Type: Article

References (48)

1. Alexanian R. Ten-year survival in multiple myeloma. Arch Intern Med 1985; 145: 2073-2074. (Pubitemid 16198409)
2. Antipova LG, Andreeva NE. (High life expectancy in multiple myeloma). Terapevticheskii arkhiv 1985; 57: 11-14.
3. Rosner F, Grunwald HW, Kalman AC. Ten-year survival in multiple myeloma: report of two cases and review of the literature. N Y State J Med 1992; 92: 316-318. (Pubitemid 23052755)
4. Tsuchiya J, Murakami H, Kanoh T, Kosaka M, Sezaki T, Mikuni C et al. Ten-year survival and prognostic factors in multiple myeloma. Japan Myeloma Study Group. Br J Haematol 1994; 87: 832-834. (Pubitemid 24264658)
5. Giaccone L, Storer B, Patriarca F, Rotta M, Sorasio R, Allione B et al. Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood 2011; 117: 6721-6727.
6. Salama M, Nevill T, Marcellus D, Parker P, Johnson M, Kirk A et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 2000; 26: 1179-1184.
7. Dhodapkar MV, Krasovsky J, Osman K, Geller MD. Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med 2003; 198: 1753-1757. (Pubitemid 37494167)
8. Joshua DE, Brown RD, Gibson J. Multiple myeloma: why does the disease escape from plateau phase? Br J Haematol 1994; 88: 667-671. (Pubitemid 24375778)
9. Brown RD, Yuen E, Nelson M, Gibson J, Joshua D. The prognostic significance of T cell receptor beta gene rearrangements and idiotype-reactive T cells in multiple myeloma. Leukemia 1997; 11: 1312-1317. (Pubitemid 27387309)
10. Brown RD, Spencer A, Ho PJ, Kennedy N, Kabani K, Yang S et al. Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma. Leuk Lymphoma 2009; 50: 1860-1864.
11. Raitakari M, Brown RD, Sze D, Yuen E, Barrow L, Nelson M et al. T-cell expansions in patients with multiple myeloma have a phenotype of cytotoxic T cells. Br J Haematol 2000; 110: 203-209. (Pubitemid 30625609)
12. Li J, Sze DM, Brown RD, Cowley MJ, Kaplan W, Mo SL et al. Clonal expansions of cytotoxic T cells exist in the blood of patients with Waldenstrom macroglobulinemia but exhibit anergic properties and are eliminated by nucleoside analogue therapy. Blood 2010; 115: 3580-3588.
13. Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009; 23: 1398-1405.
14. Epling-Burnette PK, Painter JS, Rollison DE, Ku E, Vendron D, Widen R et al. Prevalence and clinical association of clonal T-cell expansions in Myelodysplastic Syndrome. Leukemia 2007; 21: 659-667. (Pubitemid 46444549)
15. de Vries AC, Langerak AW, Verhaaf B, Niemeyer CM, Stary J, Schmiegelow K et al. T-cell receptor Vbeta CDR3 oligoclonality frequently occurs in childhood refractory cytopenia (MDS-RC) and severe aplastic anemia. Leukemia 2008; 22: 1170-1174. (Pubitemid 351833784)
16. Sze DM, Brown RD, Yuen E, Gibson J, Ho J, Raitakari M et al. Clonal cytotoxic T cells in myeloma. Leuk Lymphoma 2003; 44: 1667-1674. (Pubitemid 37221039)
17. Sze DM, Giesajtis G, Brown RD, Raitakari M, Gibson J, Ho J et al. Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(+)CD57(+)CD28(-) compartment. Blood 2001; 98: 2817-2827.
18. D'Amico A, Wu L. The early progenitors of mouse dendritic cells and plasmacytoid predendritic cells are within the bone marrow hemopoietic precursors expressing Flt3. J Exp Med 2003; 198: 293-303. (Pubitemid 36987854)
19. Goodyear O, Piper K, Khan N, Starczynski J, Mahendra P, Pratt G et al. CD8+ T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden. Blood 2005; 106: 4217-4224. (Pubitemid 41775929)
20. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007; 117: 1167-1174. (Pubitemid 46718401)
21. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007; 117: 1137-1146. (Pubitemid 46718398)
22. Joshua DE, Brown RD, Ho PJ, Gibson J. Regulatory T cells and multiple myeloma. Clin Lymphoma Myeloma 2008; 8: 283-286.
23. Law JP, Hirschkorn DF, Owen RE, Biswas HH, Norris PJ, Lanteri MC. The importance of Foxp3 antibody and fixation/permeabilization buffer combinations in identifying CD4+CD25+Foxp3+ regulatory T cells. Cytometry Part A 2009; 75: 1040-1050.
24. Minnema MC, van der Veer MS, Aarts T, Emmelot M, Mutis T, Lokhorst HM. Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells. Leukemia 2009; 23: 605-607.
25. Cao Y, Luetkens T, Kobold S, Hildebrandt Y, Gordic M, Lajmi N et al. The cytokine/ chemokine pattern in the bone marrow environment of multiple myeloma patients. Exp Hematol 2010; 38: 860-867.
26. Spencer A, Prince HM, Roberts AW, Prosser IW, Bradstock KF, Coyle L et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009; 27: 1788-1793.
27. Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998; 187: 1885-1892. (Pubitemid 28262451)
28. Feyler S, von Lilienfeld-Toal M, Jarmin S, Marles L, Rawstron A, Ashcroft AJ et al. CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+) CD4(-)CD8(-)alphabetaTCR(+) Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br J Haematol 2009; 144: 686-695.
29. Galy A, Travis M, Cen D, Chen B. Human T, B, natural killer, and dendritic cells arise from a common bone marrow progenitor cell subset. Immunity 1995; 3: 459-473.
30. Chen ML, Pittet MJ, Gorelik L, Flavell RA, Weissleder R, von Boehmer H et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci USA 2005; 102: 419-424. (Pubitemid 40116782)
31. Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999; 401: 86-90.
32. Kawabuchi M, Satomi Y, Takao T, Shimonishi Y, Nada S, Nagai K et al. Transmembrane phosphoprotein Cbp regulates the activities of Src-family tyrosine kinases. Nature 2000; 404: 999-1003. (Pubitemid 30243594)
33. Tzachanis D, Freeman GJ, Hirano N, van Puijenbroek AA, Delfs MW, Berezovskaya A et al. Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. Nat Immunol 2001; 2: 1174-1182. (Pubitemid 33130153)
34. Mateyak MK, Obaya AJ, Sedivy JM. c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points. Mol Cell Biol 1999; 19: 4672-4683. (Pubitemid 29289505)
35. Saxena M, Williams S, Gilman J, Mustelin T. Negative regulation of T cell antigen receptor signal transduction by hematopoietic tyrosine phosphatase (HePTP). J Bioll Chem 1998; 273: 15340-15344. (Pubitemid 28298136)
36. Ratta M, Fagnoni F, Curti A, Vescovini R, Sansoni P, Oliviero B et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002; 100: 230-237. (Pubitemid 35177452)
37. Schuurhuis DH, Laban S, Toes RE, Ricciardi-Castagnoli P, Kleijmeer MJ, van der Voort EI et al. Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli. J Exp Med 2000; 192: 145-150. (Pubitemid 30470816)
38. Giannopoulos K, Kaminska W, Hus I, Dmoszynska A. The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma. Br J Cancer 2012; 106: 546-552.
39. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Review Immunol 2003; 21: 685-711. (Pubitemid 37174545)
40. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001; 193: 233-238. (Pubitemid 32524454)
41. Ferguson TA, Herndon J, Elzey B, Griffith TS, Schoenberger S, Green DR. Uptake of apoptotic antigen-coupled cells by lymphoid dendritic cells and cross-priming of CD8(+) T cells produce active immune unresponsiveness. J Immunol 2002; 168: 5589-5595. (Pubitemid 34556139)
42. Fricke I, Gabrilovich DI. Dendritic cells and tumor microenvironment: a dangerous liaison. Immunol Invest 2006; 35: 459-483. (Pubitemid 44266783)
43. Dzionek A, Inagaki Y, Okawa K, Nagafune J, Rock J, Sohma Y et al. Plasmacytoid dendritic cells: from specific surface markers to specific cellular functions. Hum immunol 2002; 63: 1133-1148. (Pubitemid 36025988)
44. Pessoa-Magalhaes RJ, Vidriales MB, Paiva B, Gimenez CF, Garcia-Sanz R, Mateos MV et al. Analysis of the immune system of multiple myeloma patients achieving long-term disease control, by multidimensional flow cytometry. Haematologica 2013; 98: 79-86.
45. Dzionek A, Sohma Y, Nagafune J, Cella M, Colonna M, Facchetti F et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. J Exp Med 2001; 194: 1823-1834. (Pubitemid 34028661)
46. Maddur MS, Miossec P, Kaveri SV, Bayry J. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol 2012; 181: 8-18.
47. Prabhala RH, Pelluru D, Fulciniti M, Prabhala HK, Nanjappa P, Song W et al. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 2010; 115: 5385-5392.
48. Noonan K, Marchionni L, Anderson J, Pardoll D, Roodman GD, Borrello I. A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood 2010; 116: 3554-3563.